Spark grabs FDA nod for Luxturna, a breakthrough gene therapy likely bearing a pioneering price – FiercePharma
|
Spark grabs FDA nod for Luxturna, a breakthrough gene therapy likely bearing a pioneering price
FiercePharma Luxturna is now Spark's only approved med and works by delivering a gene called RPE65 into a patient's retinal cells, which then produce a protein to restore vision loss. The one-time treatment uses a naturally occurring adeno-associated virus to … |
